Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03647722 · ClinicalTrials.gov registry record
Assessing the Induction of Long-term Immune Regulation Following Treatment With Lemtrada® (Alemtuzumab).
A clinical trial, sponsored by University of Southern California.
- Terminated
- Registry status
- 97
- Enrollment target
NCT03647722 is a clinical trial that was terminated before completion, run by University of Southern California. The registered enrollment target is 97 participants.
The verdict
NCT03647722 was terminated before completion, sponsored by University of Southern California.
- TERMINATED
- Registry status
- 97 participants
- Enrollment target
Study Summary
In this study the investigators wish to test the hypothesis that treatment with Lemtrada is associated with alterations in immune homeostasis in favor of multiple regulatory leukocyte populations which persist long after completion of the treatment phase. Specifically, the investigators propose that regulatory B-cells are induced rapidly following the first course of treatment with Lemtrada, that this occurs prior to induction of other regulatory populations, and that these cells are functionally capable of regulating immune responses. The investigators also propose that there is a concomitant induction of functional regulatory T-cells and alternatively-activated monocytes during the first year after treatment giving a "blanket" enhanced regulatory immune profile. This study is designed primarily to identify possible mechanisms by which Lemtrada acts to modify the immune environment in recipient patients, as such the "outcome" measures are all immunological.
Interventions
- OTHER Assessment of leukocyte function.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 97 participants |
| Start Date | 2018-11-02 |
| Est. Completion | 2020-11-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03647722
The ClinicalTrials.gov registry entry for NCT03647722 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 97 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Southern California, which has 617 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Assessment of leukocyte function. is the first listed.
NCT03647722 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03647722 about?
NCT03647722 is a clinical study titled "Assessing the Induction of Long-term Immune Regulation Following Treatment With Lemtrada® (Alemtuzumab).". In this study the investigators wish to test the hypothesis that treatment with Lemtrada is associated with alterations in immune homeostasis in favor of multiple regulatory leukocyte populations which persist long after completion of the treatment phase. Specifically, the investigators propose that...
What is the current status of trial NCT03647722?
This trial is currently terminated. The enrollment target is 97 participants. The study started on 2018-11-02. Estimated completion is 2020-11-30.
What interventions are being tested in trial NCT03647722?
The interventions under investigation include: Assessment of leukocyte function. (OTHER).
Who is sponsoring clinical trial NCT03647722?
This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.